VI InterAmerican Oncology Conference
'Current Status and Future of Anti-Cancer Targeted Therapies'
October 8-9, 2015
Buenos Aires, Argentina
FIRST ANNOUNCEMENT
The VI Conference of IAOC "Current Status and Future of Anti-Cancer Targeted Therapies"
will be held in Buenos Aires, Argentina in October 8th and 9th, 2015.
An outstanding faculty of speakers from the United States and Europe has committed in this
meeting.
The conference agenda will focus on new translational advances in the treatment of cancer as well
as provide updates of conventional therapies for a number of the most common tumor types. The
meeting objectives are designed to introduce the audience to the latest information on targeted
therapies, immunotherapies and emerging treatments in early development. The major emphasis
will be on clinical aspects of cancer treatment in the 21 st century with discussion of significant
scientific advances underlying the novel approaches still in preclinical development.
This meeting is the primary opportunity for oncologists and cancer related health workers to
participate in a conference focusing on novel targeted therapies and other treatment advances
which are changing the face of cancer care.
CO- CHAIRS
Alex Adjei, Buffalo, New York, USA
Román Perez Soler, New York, USA
Josep Tabernero, Barcelona, Spain
ORGANIZING COMMITTEE
Román Pérez Soler, New York, USA
Andrea Blanco, Buenos Aires, Argentina
SCIENTIFIC COMMITTEE
Alex Adjei, M.D., Ph.D., Roswell Park Cancer Institute, Buffalo, New York, USA
Kenneth C. Anderson, M.D., Dana-Farber Cancer Institute Boston, Massachusetts, USA
Carlos L. Arteaga, M.D., Vanderbilt University School of Medicine, Nashville, USA
Hernán Cortes Funes, M.D., Hospital Universitario "12 de Octubre", Madrid, Spain
Roman Perez Soler, M.D., Albert Einstein College of Medicine, Bronx, New York, USA
Josep Tabernero, M.D., Ph.D., Vall d'Hebron University Hospital, Barcelona, Spain
FACULTY (PROVISIONARY)
Alex A. Adjei, M.D., Ph.D.
Professor and Chair, Department of Medicine
Katherine Anne Gioia Chair in Cancer Medicine
Senior Vice-President for Clinical Research
Roswell Park Cancer Institute
Buffalo, New York, USA
Kenneth C. Anderson, M.D.
Kraft Family Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts, USA
Carlos L. Arteaga, M.D.
Professor of Medicine and Cancer Biology
Director Center for Cancer Targeted Therapies
Director Breast Cancer Program
Associate Director for Clinical Research
Vanderbilt -Ingram Cancer Center
Nashville, Tennessee, USA
Jorge Cortés, M.D.
Professor of Medicine
Chief, CML & AML Sections
Deputy Chair, Department of Leukemia
M.D. Anderson Cancer Center
Houston, Texas, USA
Hernán Cortés Funes, M.D.
Department of Medical Oncology
Hospital Universitario "12 de Octubre"
Madrid, Spain
Richard Finn, M.D.
Associate Professor of Medicine
Department of Medicine
Division of Hematology/ Oncology
Geffen School of Medicine at UCLA
Los Angeles, California, USA
Román Pérez-Soler, M.D.
Chairman, Department of Oncology
Montefiore Medical Center
Albert Einstein College of Medicine
Bronx, New York, USA
2
Antoni Ribas, M.D., Ph.D.
Professor of Medicine and Surgery
Professor of Molecular and Medical Pharmacology
Director Tumor Immunology Program, Jonsson
Comprehensive Cancer Center (JCCC)
David Geffen School of Medicine, UCLA
Chair, Melanoma Committee at SWOG
Los Angeles, California, USA
Brian I. Rini, MD, FACP
Professor of Medicine, Lerner College of Medicine
Department of Solid Tumor Oncology
Cleveland Clinic Taussig Cancer Institute
Glickman Urological Institute
Cleveland, Ohio, USA
Josep Tabernero, M.D., Ph.D.,
Chairman Medical Oncology Department
Vall d'Hebron University Hospital
Barcelona, Spain
Jeffrey S. Weber, M.D., Ph.D.
Senior Member, and Director
Donald A. Adam Comprehensive
Melanoma Research Center Cutaneous Oncology
Moffitt Cancer Center
Tampa, Florida,USA
Anas Younes, M.D.
Chief of the Lymphoma Service
Memorial Sloan Kettering Cancer Center
Professor Department of Medicine
Weill- Cornell College of Medicine
New York , New York, USA
PRELIMINARY PROGRAM
NEW ANTICANCER THERAPIES

Incorporating Genomics into Clinical Trials and Clinical Practice:
Alex A. Adjei, Buffalo, USA

Development of New Cell Cycle Inhibitors:
Richard Finn, California, USA

Immune Checkpoint Inhibitors (anti-PD1 and anti-PDL1):
Antoni Ribas, California, USA

The impact of New Marine Compounds in Cancer Therapy:
Hernán Cortés Funes, Madrid, Spain.

Clinical Perspectives on the Expanding Role of Immuno-Oncology:
Jeffrey S. Weber, Tampa, USA
3
WOMEN´S CANCER

Novel Combinations with PI3K/TOR Pathway Inhibitors:
Carlos L. Arteaga, Nashville, USA

Current and Future Treatments in Breast Cancer:
Hernán Cortés Fúnes, Madrid, Spain

Gynecological Cancer:
TBA
GU CANCER

Targeting the Androgen Axis in Metastatic Prostate Cancer:
Brian Rini, Cleveland, USA

The Evolution of Targeted Therapy for Metastatic Renal Cell Carcinoma:
Brian Rini, Cleveland, USA
GI CANCER

New Therapies in the Treatment of Gastric Cancer:
Josep Tabernero, Barcelona, Spain

Treatment for Advanced Colorectal Cancer:
Josep Tabernero, Barcelona, Spain
LUNG CANCER

Management of NSCLC with Known Activating Mutations:
Alex A. Adjei, New York, USA

Management of NSCLC without Activating Mutations:
Román Pérez Soler, New York, USA

Current and Future Management of ALK Rearranged NSCLC:
Román Pérez Soler, New York, USA
HEMATOLOGICAL MALIGNANCIES

New Developments in Lymphoma:
Anas Younes, New York, USA

Multiple Myeloma:
Kenneth C. Anderson, Boston, USA

Novel Drug Development in Leukemia:
Jorge Cortés, Houston, USA
4
CONFERENCE SECRETARIAT AND INFORMATION
E-mail: secretariat@oncologyconferences.com.ar
Web: www.oncologyconferences.com.ar
5